
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the first patient in a trial to test the effectiveness of buntanetap on early Parkinson’s Disease was recently dosed.
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease Read More